Advertisement

Topics

Latest "Sitka Limited" News Stories

21:41 EDT 24th September 2018 | BioPortfolio

Here are the most relevant search results for "Sitka Limited" found in our extensive news archives from over 250 global news sources.

More Information about Sitka Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Sitka Limited for you to read. Along with our medical data and news we also list Sitka Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Sitka Limited Companies for you to search.

Showing "Sitka Limited" News Articles 1–25 of 396

Saturday 22nd September 2018

AsiaPacific Pea Protein Market Growth, Trends and Forecasts 2018 2023 [Report Updated: 01032018] Prices from USD $3850

The AsiaPacific pea protein market records a revenue of USD 20.9 million in 2016, and is expected to grow at a CAGR of 8.4% during the forecast period 20182023.The health benefits of protein intake from fast muscle recovery to weigh control is driving protein uptake. Its use in functional foods in Asian market makes it the most trending in plant protein segment. Pea protein is generally used as a ...


Friday 21st September 2018

Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases.

Oxford, UK, 20 September 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU ...

Thursday 20th September 2018

Medtronic to Acquire Mazor Robotics

  Acquisition to Accelerate Medtronic's Strategy to Transform Spinal Procedures and Improve Outcomes Through Fully-Integrated Surgical Solutions DUBLIN and CAESAREA, Israel - September 20, 2018 - Medtronic plc (NYSE:MDT), a global leader in medical technology, and Mazor Robotics (NASDAQ:MZOR, TASE:MZOR.TZ), a pioneer in the field of robotic guidance systems, today announced th...


Wednesday 19th September 2018

ECVAM evaluation of GARDskin rescheduled to an extra scientific committee meeting in spring 2019

Lund, September 18, 2018 - SenzaGen (Nasdaq First North: SENZA) has been notified by the European Center for the Validation of Alternative Methods (ECVAM) authority that due to time constrains their scientific committee (ESAC) will not be able to evaluate tests in the category ”Test Guidelines on Health Effects”, to which GARDskin belongs, this year. The authority cites high workload...

Tuesday 18th September 2018

Evonetix makes key appointments to support development of novel gene synthesis technology

CAMBRIDGE, UK, 18 September 2018 – EVONETIX LTD (‘Evonetix’), the company pioneering an innovative approach to scalable and high-fidelity gene synthesis, announced today that it has expanded its team three-fold, following a successful series A round of £9 million ($12.3M) to support the development of the Company’s technology. The appointments include physicis...

Monday 17th September 2018

Metrion Biosciences makes senior appointments to strengthen its drug discovery leadership team.

Dr Edward Stevens appointed as Head of Drug Discovery, and Dr Andrew Lightfoot as Head of Medicinal Chemistry and Discovery Funding Cambridge, UK, 17 September 2018: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has made two senior appointments to its management team.  Dr Edward Steve...

Tuesday 11th September 2018

Stryker announces definitive agreement to acquire Invuity, Inc.

Kalamazoo, Michigan - September 11, 2018 - Stryker (NYSE: SYK) announced today a definitive agreement to acquire all the issued and outstanding shares of common stock of Invuity, Inc. (NASDAQ: IVTY) for $7.40 per share, or a total equity value of approximately $190 million. Invuity is the leader in advanced photonics and single-use, lighted instruments that deliver enhanced visuali...

Monday 10th September 2018

Biopharma Company Arecor raises £6m for revolutionary diabetes treatments

10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures.  BioScience Managers Limited, the international healthcare investment firm...

TexRAD® ordered by Samsung Medical Centre in South Korea

Cambridge, UK, 10 September 2018: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received an order from its South Korean distributor for TexRAD®, its patented image texture analysis technology, for the Samsung Medical Centre in Seoul. The order cam...

Glythera Limited Announces Corporate Name Change and Rebranding to Iksuda Therapeutics

New identity reflects transition in corporate focus, from technology licensing to drug development, for previously untreatable cancers Newcastle, UK, 10th September, 2018: Glythera Limited (Glythera), the next-generation Antibody Drug Conjugate (ADC) development company, today announced that it has changed its name to Iksuda Therapeutics (Iksuda) and unveiled a new corporate brand. The new ...

Xbrane Biopharma announces product portfolio update with a new full strategic focus on biosimilars

Press release2018-09-10 The board of directors of Xbrane Biopharma (publ.) ("Xbrane" or the Company) has decided to shift strategic focus in the Company's product pipeline to biosimilars. As Xbranes leading biosimilar Xlucane (ranibizumab (Lucentis®) biosimilar) moves into the pivotal clinical trial, Xbrane is accelerating development of Xcimzane (certoizumab pegol...

Friday 7th September 2018

DBV Technologies : Reports First Half 2018 Financial Results

Montrouge, France, September 7, 2018 DBV Technologies Reports First Half 2018 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2018 financial results. The interim financial report is available on the Investor Relations section of the Company's websi...

Thursday 6th September 2018

argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis

September 6, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the dosing of the first patient in a global Phase 3 registration trial of efgartigimod (ARGX-113) in...

Wednesday 5th September 2018

Metrion Biosciences and AMRI collaborate to offer ion channel drug discovery services

Agreement enables customers to access a broader range of drug discovery expertise CAMBRIDGE, UK and ALBANY, NY, 05 September 2018: Metrion Biosciences Limited (“Metrion”), the specialist ion channel CRO and drug discovery company, and AMRI, a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes a...

Tuesday 4th September 2018

Stryker to participate in Morgan Stanley 16th Annual Global Healthcare Conference

Kalamazoo, Michigan - September 4, 2018 - Stryker (NYSE:SYK) will participate in the Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday, September 12, 2018 at the Grand Hyatt New York in New York City. Katherine Owen, Vice President, Strategy and Investor Relations, will represent the Company in a presentation scheduled for 9:55 a.m. Eastern Time. A simultaneous w...

Monday 3rd September 2018

Walcom Group Ltd - Receipt of initial customer payment

Walcom Group Ltd - Receipt of initial customer payment PR Newswire London, September 3 3 September 2018 WALCOM GROUP LIMITED ("Walcom" or "the Company") Receipt of initial customer payment Further...

Sanofi: Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

Press ReleaseSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP) First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder In addition, U.S. FDA to conduct priority review of caplacizumab with a target action date of February 6, 2019 Paris - ...

Thursday 30th August 2018

Bone Therapeutics SA announces H1 results for 2018

Regulated information The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Bone Therapeutics in the section 'Financial information'.Bone Therapeutics publishes its interim financial report in English. A...

Biocartis Group NV: Biocartis announces 2018 half-year results on 6 September 2018

PRESS RELEASE: REGULATED INFORMATION Thursday 30 August 2018, 07:00 CEST BIOCARTIS ANNOUNCES 2018 HALF-YEAR RESULTS ON 6 SEPTEMBER 2018 Mechelen, Belgium, 30 August 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it will report its half-year 2018 results and outlook ...

Wednesday 29th August 2018

argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis

August 29, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it has received feedback from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan on the desi...

Tuesday 28th August 2018

Global Smart Packaging Market Segmented by Active Packaging Oxygen Scavengers, Microwave Susceptors, Odor Absorbers, Intelligent Packaging Shelf life Sensing, Temperature Indicators, RFID, Modified Atmosphere Packaging BagSealing Machine, Horizontal amp;

The global smart packaging market is expected to register a CAGR of 4.28% during the forecast period, 20182023. The report discusses the types of packaging technologies and its segments in detail, while the regions considered in the scope of the report include North America, Europe, and various others. The study also focuses on various trends in the market, such as the increasing demand for longer...

Metrion Biosciences awarded £637k funding under Innovate UK Biomedical Catalyst Primer Award for ion channel drug discovery

Funding will support project aiming to identify novel oral therapeutics for the auto-immune disease psoriasis Adds to Innovate UK funding awarded in February 2018 for research on potassium channel inhibitors Cambridge, UK, 28 August 2018: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it h...

Kiadis Pharma to attend upcoming investor conferences in September 2018

Kiadis Pharma to attend upcoming investor conferences in September 2018 Amsterdam, The Netherlands, August 28, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing a patient-specific T-cell product designed to be delivered following a haploidentical hematopoietic stem ce...

Friday 24th August 2018

Global Food Certification Market Global Trends Forecasts 2018 2023 [Report Updated: 01032018] Prices from USD $4250

The global food certification market is expected to reach USD 17.56 million by 2023, witnessing a CAGR of 6.3% during 20182023 forecast period. Increasing concerns for safe and healthy food drive the food certification market growth.Market DynamicsThe has been a monumental shift in the type of food products preferred by most consumers, they are becoming aware about food safety and quality and the...

Kiadis Pharma to announce Financial Results for the six months ended June 30, 2018

                                                   Kiadis Pharma to announce Financial Results for the six months ended June 30, 2018 Amsterdam, The Netherlands, August 24, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical comp...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks